Edition:
India

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

15.75USD
1:30am IST
Change (% chg)

$-0.10 (-0.63%)
Prev Close
$15.85
Open
$16.12
Day's High
$16.16
Day's Low
$15.53
Volume
3,918
Avg. Vol
10,437
52-wk High
$27.83
52-wk Low
$10.50

Latest Key Developments (Source: Significant Developments)

Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Arsanis Inc ::LICENSES PRECLINICAL STAGE E. COLI MONOCLONAL ANTIBODIES.BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI.  Full Article

Arsanis Reports Q4 Net Loss $1.68 Per Share
Friday, 9 Mar 2018 

March 9 (Reuters) - Arsanis Inc ::ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017.ARSANIS INC - FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2017, ARSANIS REPORTED NET LOSS OF $1.68 LOSS PER SHARE.ARSANIS INC - AS OF DECEMBER 31, 2017, ARSANIS'S CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND INVESTMENTS TOTALED $76.8 MILLION.  Full Article

Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Arsanis Inc ::ARSANIS INC FILES TO SAY IT HAS RAISED $20 MILLION IN EQUITY FINANCING - SEC FILING.  Full Article

OrbiMed Advisors Reports 13.07 Percent Stake In Arsanis As Of Nov 20 - SEC Filing ‍​
Friday, 1 Dec 2017 

Nov 30 (Reuters) - OrbiMed Advisors LLC::ORBIMED ADVISORS LLC REPORTS 13.07 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20 - SEC FILING ‍​.ORBIMED ADVISORS LLC - CAUSED OPI IV TO ACQUIRE COMMON STOCK OF THE ARSANIS INC FOR THE PURPOSE OF MAKING AN INVESTMENT.  Full Article

Terrance G. Mcguire Reports A 13.7 Percent Stake In Arsanis Inc As Of November 20, 2017 - SEC Filig
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Arsanis Inc ::TERRANCE G. MCGUIRE REPORTS A 13.7 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20, 2017 - SEC FILIG.  Full Article

New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - NEW ENTERPRISE ASSOCIATES 16 L.P:NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING.  Full Article

Arsanis Inc shares debut about 30 pct above IPO price‍​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - :Arsanis Inc shares open at $13.00 in debut on the NASDAQ versus IPO price of $10.00 per share‍​.  Full Article

Arsanis prices initial public offering of 4 mln common shares at $10 per share​
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Arsanis Inc -:Arsanis announces pricing of initial public offering.‍Announced pricing of initial public offering of 4,000,000 shares of common stock at public offering price of $10.00 per share​.  Full Article

Arsanis Inc now sees IPO of 4 mln shares of common stock
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Arsanis Inc :Arsanis Inc now sees IPO of 4.0 million shares of common stock - sec filing‍​.Arsanis Inc says estimated initial public offering price is $10.00 per share.Arsanis Inc says had previously expected IPO of up to 3.13 million shares of common stock to be priced between $15 and $17 per share.Arsanis says intends to use about $34 million of IPO proceeds to fund development of asn100 for prevention of S. Aureus Pneumonia.  Full Article

Arsanis Inc sees IPO of up to 3.13 mln shares of common stock to be priced between $15 and $17 per share
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Arsanis Inc ::Arsanis Inc sees IPO of up to 3.13 million shares of common stock to be priced between $15 and $17 per share - SEC filing.  Full Article

BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies

* BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)